Harvest One Cannabis (TSXV:HVT,OTCQX:HRVOF) Senior VP of Corporate Affairs Will Stewart believes that the company’s cannabis oil license will be an integral component of the business.

In the interview below, Stewart provided an overview of the company, its subsidiaries and its consumer packaged goods (CPG) strategy. Harvest One’s subsidiary, United Greeneries, was recently awarded its cannabis oil license from Health Canada. According to Stewart, the license will be an integral part of the company’s story moving forward.

The license provides Harvest One with the opportunity to infuse its products with CBD and THC through the company’s CPG division. The division currently produces two products: Dream Water and LivRelief. Dream Water is a natural sleep aid that is available in 30,000 stores across North America. LivRelief is a topical pain relief cream in 6,000 stores in Canada, and Harvest One has plans to roll out the brand in the US as well.

With the oil license in hand, Harvest One intends to develop new products for the second wave of cannabis legalization in Canada. The company also plans to bring its Satipharm Gelpell® capsules into North America in the near term.

Below is a transcript of our interview with Harvest One Senior VP of Corporate Affairs Will Stewart. It has been edited for clarity and brevity.

Investing News Network: What’s your name, company and ticker symbol?

Harvest One Senior VP Corporate Development Will Stewart: I’m Will Stewart, the senior vice president of Harvest One. We’re trading on the TSXV under the ticker HVT.

INN: Please provide our investor audience with an overview of Harvest One and its subsidiaries.

WS: Harvest One is a bit of a different type of cannabis company. We grow and sell premium indoor flower in Duncan, British Columbia. We sell that flower under our recreational Captain’s Choice and Royal High brands in four provinces as well as medically through Shoppers Drug Mart under the Satipharm brand.

We have a different company in Europe, called Satipharm, with a proprietary gel pell capsule. It’s a CBD extract that comes in a 10 milligram or 50 milligram format and is sold in 2,000 stores in the UK, online across Europe and by prescription in Australia. We also have a CPG division with two products. Dream Water, a natural sleep aid, is available in 30,000 stores across North America and LivRelief, a topical pain relief cream, is available in 6,000 stores in Canada and soon in the US as well.

INN: What does United Greeneries’ cannabis oil license amendment mean for the company?

WS: Harvest one is a global health, wellness and self-care company. We’ll be looking to infuse our products with CBD and THC through our CPG division. Our oil license is an essential part of our path forward as we begin to formulate those products for Cannabis 2.0 in Canada as well as the hemp extract market in the US. We’re adding more products to our portfolio in the EU under the Satipharm brand.

INN: Harvest One seems to be evolving into a CPG company, can you talk about this strategy when it comes to Dream Water and Delivra?

WS: At the end of the day, we’re a self-care company. It’s important that we grow and sell premium flower in Canada, but our license gives us the ability to start formulating different versions of our existing CPG brands. We firmly believe that cannabis takes off when you give people products that they know, trust and buy in regular retailers like Shoppers Drug Mart and Walmart (NYSE:WMT). The world starts to change when we infuse products with cannabis, and people begin to migrate over to those product SKUs. As we move forward, our oil license will give us the ability to make value-added products a core part of our strategy.

INN: Can you talk about Satipharm in Europe and your plans for its North America one?

WS: Satipharm has a proprietary gel pill that is different than the other pills currently on the market. It has tiny micro-gelatin beads inside of a gastro-resistant capsule. The capsule can move through your stomach before it’s digested to break down in the intestine. We’ve done clinical trials on it for pediatric epilepsy that have been published in a peer-reviewed medical journal. The product is going to be a game-changer once we introduce it in North America and expand our reach across the EU and into Australia. Satipharm’s product is key for us going forward, and we’re looking to bring that product into both Canada and the US quickly.

INN: What’s next for Harvest One, and how does that fit for the company’s long-term goals?

WS: The big catalyst for us will be our new cannabis products for Cannabis 2.0 in Canada and hemp-infused products in the US. To publicize this, we’ve signed a global endorsement deal with Toronto Maple Leafs’ superstar Auston Matthews. He has been using Dream Water for about 1.5 years now and swears by the product. He says that the good night’s sleep that Dream Water allows him to have is crucial to him perform at the top of his game.

This interview is sponsored by Harvest One Cannabis (TSXV:HVT,OTCQX:HRVOF). This interview provides information which was sourced by the Investing News Network (INN) and approved by Harvest One Cannabis in order to help investors learn more about the company. Harvest One Cannabis is a client of INN. The company’s campaign fees pay for INN to create and update this interview.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Harvest One Cannabis and seek advice from a qualified investment advisor.

This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less